Analysis of IL6‑protein complexes in chondrosarcoma
- Authors:
- Karina Galoian
- Shihua Luo
- Parthik Patel
View Affiliations
Affiliations: Miller School of Medicine, Department of Orthopedics, University of Miami, Miami, FL 33136, USA
- Published online on: November 10, 2017 https://doi.org/10.3892/br.2017.1016
-
Pages:
91-98
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Cytokines produced in the tumour microenvironment serve important roles in cancer pathogenesis or in the supression of disease progression. Metastatic chondrosarcoma is a cancer of the cartilage, and our group previously reported from a human ELISA assay that interleukin 6 (IL6) expression in JJ012 chondrosarcoma cells was 86‑fold lower than that in C28 chondrocytes, indicating its role as an anti‑inflammatory and anti‑tumorigenic factor. Additionally, to the best of our knowledge, the study was the first to demonstrate downregulation of IL6 in a human chondrosarcoma cell line. To fully elucidate the effect of this IL6 downregulation, it is important to identify protein complexes and components that bind IL6 and potentially affect its gene expression directly or indirectly. To investigate IL6‑protein interactions leading to these differences in IL6 expression, the current study performed a gel retardation electrophoretic mobility shift assay (EMSA), followed by 2D gel phoresis, in‑gel trypsin digestion and proteomic mass spectral analysis. The results indicated a presence of ubiquitination enzymes in C28 chondrocytes, while none were identified in JJ012 chondrosarcoma cells. While it seems counterintuitive, it may be that the absence of ubiquitination of certain factors leads to the downregulation of IL6 expression in human chondrosarcoma. Therefore, dysregulated ubiquitination may be among the possible mechanisms for the markedly reduced IL6 expression in chondrosarcoma.
View References
|
1
|
Grivennikov SI and Karin M: Inflammation
and oncogenesis: A vicious connection. Curr Opin Genet Dev.
20:65–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andreou D, Ruppin S, Fehlberg S, Pink D,
Werner M and Tunn PU: Survival and prognostic factors in
chondrosarcoma: Results in 115 patients with long-term follow-up.
Acta Orthop. 82:749–755. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mirra J, Picci P and Gold RH: Bone Tumors:
Clinical, Radiologic, and Pathologic Correlations. 2nd. Lea and
Febiger; Philadelphia: 1989
|
|
4
|
Ozaki T, Hillmann A, Lindner N, Blasius S
and Winkelmann W: Metastasis of chondrosarcoma. J Cancer Res Clin
Oncol. 122:625–628. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galoian K, Scully S, McNamara G, Flynn P
and Galoyan A: Antitumorigenic effect of brain proline rich
polypeptide-1 in human chondrosarcoma. Neurochem Res. 34:2117–2121.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galoian K, Temple HT and Galoyan A: mTORC1
inhibition and ECM-cell adhesion-independent drug resistance via
PI3K-AKT and PI3K-RAS-MAPK feedback loops. Tumour Biol. 33:885–890.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galoian K, Luo S, Qureshi A, Patel P,
Price R, Morse AS, Chailyan G, Abrahamyan S and Temple HT: Effect
of cytostatic proline rich polypeptide-1 on tumor suppressors of
inflammation pathway signaling in chondrosarcoma. Mol Clin Oncol.
5:618–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Revel M: Growth regulatory functions of
IL6 and antitumour effects. Res Immunol. 143:769–773. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Basolo F, Fiore L, Pollina L, Fontanini G,
Conaldi PG and Toniolo A: Reduced expression of interleukin 6 in
undifferentiated thyroid carcinoma: In vitro and in vivo studies.
Clin Cancer Res. 4:381–387. 1998.PubMed/NCBI
|
|
10
|
Mulé JJ, McIntosh JK, Jablons DM and
Rosenberg SA: Antitumor activity of recombinant interleukin 6 in
mice. J Exp Med. 171:629–636. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang D, Jia Y and Jarrett HW:
Transcription factor proteomics: Identification by a novel gel
mobility shift-three-dimensional electrophoresis method coupled
with southwestern blot and high-performance liquid
chromatography-electrospray-mass spectrometry analysis. J
Chromatogr A. 1218:7003–7015. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsui KH, Wang SW, Chung LC, Feng TH, Lee
TY, Chang PL and Juang HH: Mechanisms by which interleukin-6
attenuates cell invasion and tumorigenesis in human bladder
carcinoma cells. Biomed Res Int. 2013:7912122013. View Article : Google Scholar : PubMed/NCBI
|
